If a patient on feminizing hormone therapy (oral 17β‑estradiol and spironolactone) decides to stop treatment, can the medication cause physical changes that impair fertility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Feminizing Hormone Therapy and Fertility After Discontinuation

Yes, prolonged exposure to estradiol and spironolactone can cause potentially irreversible testicular damage that may permanently impair fertility, even after stopping treatment. 1

Critical Fertility Concerns

The most important evidence comes from the 2009 Endocrine Society guidelines, which explicitly state that "prolonged exposure of the testes to estrogen has been associated with testicular damage" and critically, "restoration of spermatogenesis after prolonged estrogen treatment has not been studied." 1 This means we lack data on whether fertility can fully recover after extended feminizing hormone therapy.

Physical Changes That May Impair Fertility

Testicular Effects:

  • Estrogen causes direct testicular tissue damage with prolonged exposure 1
  • Testicular volume decreases during treatment 1
  • Spermatogenesis suppression ranges from oligospermia to complete azoospermia 2
  • Recent 2026 research demonstrates heterogeneous treatment effects, with some individuals showing complete loss of germ cells (Sertoli cell-only tubules) while others retain spermatogonial precursors 3

Recovery Timeline Uncertainty:

  • In males with hypogonadotropic hypogonadism treated with exogenous testosterone, recovery of sperm occurs in "most" but not all azoospermic males 2
  • Recovery time is "prolonged and can be months or rarely years" 2
  • However, these data come from testosterone therapy, not estrogen plus antiandrogen therapy—the effects may be worse with feminizing regimens

Spironolactone-Specific Concerns

The FDA label for spironolactone reveals additional fertility risks 4:

Direct Reproductive Toxicity:

  • Spironolactone's antiandrogenic activity can adversely affect male sex differentiation
  • Animal studies at 200 mg/kg/day showed feminization of male fetuses
  • At 50-100 mg/kg/day, offspring showed dose-dependent decreases in reproductive organ weights and endocrine dysfunction persisting into adulthood 4

Impaired Fertility Mechanisms:

  • Inhibits ovulation (relevant if ovarian tissue present)
  • Reduces circulating estrogen in females, impairing mating and fertility
  • At 100 mg/kg/day in mice, decreased conception rates and implantation 4

Clinical Reality: Variable Treatment Effects

Recent 2026 research identified four distinct response patterns among individuals on similar cyproterone acetate doses 3:

  1. Cluster 1 (12.5%): Retained round/elongated spermatids and highest spermatogonial reserves
  2. Cluster 2 (16.7%): Spermatogonia only, with inadequate testosterone suppression
  3. Cluster 3 (41.7%): Suppressed to spermatogonial level with desired hormone levels
  4. Cluster 4 (29.2%): Highest rate of Sertoli cell-only tubules and complete germ cell loss (oldest individuals)

This heterogeneity means fertility preservation potential varies dramatically between individuals and cannot be predicted in advance.

Evidence of Potential Recovery

A 2025 case series offers limited hope: 2 of 3 transgender women on hormones for 6-21 years successfully retrieved and cryopreserved sperm using extended sperm search techniques, despite azoospermia on conventional analysis 5. However, this required specialized procedures and was not successful in all cases.

Practical Counseling Points

Before stopping treatment, patients must understand:

  1. Fertility may not return: The Endocrine Society explicitly states restoration of spermatogenesis after prolonged estrogen has not been studied 1

  2. Recovery requires testosterone exposure: If spermatogenesis recovers, it will be "associated with physical manifestations of testosterone production" 1—meaning masculinizing changes will occur during any fertility recovery attempt

  3. Timeline is unpredictable: Recovery takes 6-12 months minimum in hypogonadotropic men, but may take years or never occur 2

  4. Age matters: Older individuals show more complete germ cell loss 3

  5. Spironolactone adds risk: Beyond estrogen effects, spironolactone has independent antiandrogenic and reproductive toxicity 4

Recommendation Algorithm

For patients considering stopping feminizing hormone therapy:

  • Counsel that fertility impairment may be permanent based on testicular damage from prolonged estrogen exposure 1
  • Explain that even if recovery occurs, it requires months to years and involves re-masculinization 2, 1
  • Consider referral to reproductive endocrinology for gonadotropin stimulation (hCG/FSH) if fertility desired 2
  • Offer specialized sperm retrieval techniques (extended sperm search, testicular extraction) as recovery attempts may fail with conventional methods 5
  • Strongly emphasize fertility preservation (sperm banking) before initiating hormone therapy as the only reliable option 1

The evidence clearly shows that while some fertility recovery is possible, it is unpredictable, may be incomplete or absent, and requires acceptance of re-masculinization during the recovery period.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.